Arch Pharmalabs completes Gurgaon facility expansion

58 Investors following Arch Pharmalabs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Arch Pharmalabs completes Gurgaon facility expansion

Arch Pharmalabs Limited announced the opening of its expanded operations at its Gurgaon site. Christened as “Project Paschim”, the project was initiated around a year back and has now been completed and ready for commencement of production

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS DSM Anti-Infectives partners with Arch Pharmalabs Fitch affirms Arch Pharmalabs CP/STD prog at F1(ind) Aventis Pharma an mkt performer, tgt Rs 1025: Karvy GSK Pharma gains from vaccines, priority products ALSO READ See latest News about Arch Pharmalabs See previous management interviews See what other Experts & Brokerages are saying about Arch Pharmalabs BSE | NSE 01/01/70 Are Mutual Funds betting on ? Other Stocks in this news Ranbaxy Laboratories |

Arch Pharmalabs Limited today announced the opening of its expanded operations at its Gurgaon site.  Christened as "Project Paschim", the project was initiated around a year back and has now been completed and ready for commencement of production.

Mr. Malvinder Mohan Singh, CEO and MD- Ranbaxy Laboratories Limited, formally inaugurated the facility today.

The project built at a cost of over Rs 50 crores comprises of four manufacturing plants, enhanced utilities and top of the line effluent treatment facilities. A state of the art Pilot Plant has also been built which will address the Contract Manufacturing ambitions of the company and will produce compounds for both pre-clinical and clinical requirements of innovator companies.

Commenting on the opening, Ajit Kamath, Chairman & MD, Arch Pharmalabs said "Project Paschim, as the name suggests, is aimed at aggressively targeting the key western markets of US and Europe and will dedicatedly & solely manufacture Active Pharmaceutical Ingredients (APIs)."

The facility currently plans manufacture of APIs in the Cardiovascular, Immuno Supressants, Anti Retrovirals (HIV) and Anti Malarials. The latter two aim to be a part of various foundation related programmes like PEPFAR, WHO etc. The site is expected to face inspection by the USFDA in the first half of the current calendar year.

Further commenting Mr. Ajit Kamath stated that "At 100% utilization by (2009) the site is expected to contribute close to Rs.250 Crores to the topline of Arch Pharmalabs Limited. To achieve this target, Arch has embarked on an aggressive DMF filing programme. We plan to file a minimum of 6 DMF's every calendar year."

The company has tie-ups with leading technology partners like Codexis Inc (USA) and DSM (Netherlands) for co-development and manufacture of APIs and advanced intermediates using proprietary technology. The Gurgaon site is expected to be the site for launch of various APIs under these partnership agreements.

Sourced From: Adfactors Public Relations Pvt Ltd